MK2 Inhibitors for Selective p38 MAPK Axis Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current p38 MAPK inhibitors face challenges in clinical settings due to safety concerns and limited efficacy in treating inflammatory conditions.
Innovation Solution
Development of novel MK2 inhibiting compounds and pharmaceutical compositions that selectively target the p38/MK2 axis, offering enhanced potency and improved safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If p38 MAPK inhibitors are used to treat inflammatory conditions, then anti-inflammatory efficacy is improved, but safety concerns arise
Solution Approach 1:
The patent segments the broad p38 MAPK inhibition into a more specific p38/MK2 axis inhibition. By designing compounds that selectively target the p38/MK2 interaction rather than broadly inhibiting all p38 MAPK substrates, the invention divides the inhibitory effect to achieve better therapeutic selectivity. This segmentation allows the drug to address inflammatory conditions while potentially reducing off-target effects that cause safety concerns.
Solution Approach 2:
The invention applies local quality by creating compounds with specific structural features (Formula I compounds with particular substituent patterns) that confer selective inhibition of the p38/MK2 axis. The local chemical structure modifications at specific positions (R1, R2, R3, R4, R5, R6 groups) are designed to optimize binding to the p38/MK2 interface while avoiding other p38 substrates, thereby improving safety through targeted action.
2Object-affected harmful factors
If selective p38/MK2 axis inhibition is achieved, then safety profile is improved, but potency may be limited
Solution Approach 1:
The patent employs parameter changes by systematically varying the chemical parameters of the Formula I compounds (different R groups, ring structures, substituent positions) to optimize both potency and selectivity. By adjusting these molecular parameters, the invention achieves compounds that maintain high potency against the p38/MK2 axis while preserving the improved safety profile through selective targeting.
Data Source
AI summary
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including rheumatoid arthritis.